31 min
The Science and Art of De-risking Cancer Drug Development | Talking Precision Medicine #35 Talking Precision Medicine
-
- Scienze biologiche
In this episode Genialis CEO Rafael Rosengarten sat down with Dr. Carolina Haefliger, head of translational medicine at Debiopharm, the privately held Swiss biopharma company focused on oncology drug development. They talked about de-risking promising new cancer drugs, and what it takes from the science to the team to the technologies.
Episode 35 links:
Visit TPM E35 for highlights and links from this episode >
Learn more about Genialis™ krasID >
New Genialis RNA Biomarker Accurately Predicts KRAS Outcomes in Lung Cancer Patients >
In this episode Genialis CEO Rafael Rosengarten sat down with Dr. Carolina Haefliger, head of translational medicine at Debiopharm, the privately held Swiss biopharma company focused on oncology drug development. They talked about de-risking promising new cancer drugs, and what it takes from the science to the team to the technologies.
Episode 35 links:
Visit TPM E35 for highlights and links from this episode >
Learn more about Genialis™ krasID >
New Genialis RNA Biomarker Accurately Predicts KRAS Outcomes in Lung Cancer Patients >
31 min